for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CSPC Pharmaceutical Group Ltd

1093.HK

Latest Trade

17.40HKD

Change

0.50(+2.96%)

Volume

33,956,018

Today's Range

16.84

 - 

17.58

52 Week Range

9.90

 - 

19.26

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
16.90
Open
16.92
Volume
33,956,018
3M AVG Volume
826.48
Today's High
17.58
Today's Low
16.84
52 Week High
19.26
52 Week Low
9.90
Shares Out (MIL)
6,236.34
Market Cap (MIL)
108,512.30
Forward P/E
24.76
Dividend (Yield %)
1.03

Next Event

Q3 2019 CSPC Pharmaceutical Group Ltd Earnings Release

Latest Developments

More

CSPC Pharma Says Humanized Says Antibody Granted Rare Pediatric Disease Designation By FDA

CSPC Pharmaceutical Group Says Glutathione For Injection Granted Drug Registration Approval

CSPC Pharmaceutical Gets Drug Registration Approval For An Anti-Diabetic Drug

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CSPC Pharmaceutical Group Ltd

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.

Industry

Biotechnology & Drugs

Contact Info

No. 226 Huanghe Avenue

+86.311.87037015

http://www.cspc.com.hk/

Executive Leadership

Dongchen Cai

Executive Chairman of the Board, Chief Executive Officer

Cuilong Zhang

Executive Vice Chairman of the Board, Rotating Chief Executive Officer

Kin Man Chak

Executive Director

Chunlei Li

Executive Director

Hua Lu

Executive Director

Key Stats

1.71 mean rating - 31 analysts
Sell
Hold
Buy
Revenue (MM, HKD)

2016

12.4K

2017

15.5K

2018

21.0K

2019(E)

25.2K
EPS (HKD)

2016

0.350

2017

0.455

2018

0.586

2019(E)

0.694
Price To Earnings (TTM)
28.33
Price To Sales (TTM)
4.86
Price To Book (MRQ)
5.94
Price To Cash Flow (TTM)
23.79
Total Debt To Equity (MRQ)
1.59
LT Debt To Equity (MRQ)
0.77
Return on Investment (TTM)
22.13
Return on Equity (TTM)
14.97

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up